MARAVAI LIFESCIENCES HOLDINGS, INC.
MRVIdata completeness 100%7 fiscal years on fileMARAVAI LIFESCIENCES HOLDINGS, INC. earns about 17% on invested capital, and has bought back 44% of its shares over 5 years. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $799.2M1 | $883M2 | $288.9M3 | $259.2M3 | $185.7M3 |
| Net income | $182M4 | $220.2M5 | −$119M6 | −$144.8M6 | −$130.8M6 |
| Operating cash flow | $368.6M7 | $536M8 | $126.2M9 | $7.47M9 | −$57.6M9 |
| Capital expenditure | $14.9M10 | $17.1M11 | $65.6M12 | $29.7M12 | $13.1M12 |
| Free cash flow (derived) | $353.7M7 | $518.9M8 | $60.7M9 | −$22.2M9 | −$70.7M9 |
| Total debt | $1.06B13 | $1.05B14 | $1.05B15 | $591.9M16 | $583.5M16 |
| Cash & equivalents | $551.3M17 | $632.1M18 | $575M19 | $322.4M20 | $216.9M20 |
| Diluted shares | 257.8M | 255.3M | 131.9M | 137.9M | 144.4M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $14.71 of net worth that earned you −$9.06 and generated −$4.9 of cash last year, against $40.42 of debt.
It earned an average 17% on invested capital over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is down 44% over 5 years — management has been buying back stock, quietly handing owners a bigger slice. Total debt has fallen 45% — deleveraging.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-12-31 · accession 0001823239-24-000032 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0001823239-25-000034 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0001823239-26-000011 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0001823239-24-000032 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0001823239-25-000034 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0001823239-26-000011 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0001823239-24-000032 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0001823239-25-000034 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0001823239-26-000011 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0001823239-24-000032 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2022-12-31 · accession 0001823239-25-000034 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2023-12-31 · accession 0001823239-26-000011 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2021-12-31 · accession 0001823239-23-000014 (LongTermDebtNoncurrent)
- 10-K · period ending 2022-12-31 · accession 0001823239-24-000032 (LongTermDebtNoncurrent)
- 10-K · period ending 2023-12-31 · accession 0001823239-25-000034 (LongTermDebtNoncurrent)
- 10-K · period ending 2024-12-31 · accession 0001823239-26-000011 (LongTermDebtNoncurrent)
- 10-K · period ending 2021-12-31 · accession 0001823239-25-000034 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)
- 10-K · period ending 2022-12-31 · accession 0001823239-24-000032 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0001823239-25-000034 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2024-12-31 · accession 0001823239-26-000011 (CashAndCashEquivalentsAtCarryingValue)